Hypothesis

Individuals with a high plasma NAD+ to α‑ketoglutarate (AKG) ratio before supplementation will experience a greater reduction in epigenetic age after calcium AKG (Ca‑AKG) treatment because this ratio optimizes TET enzyme activity while preserving sirtuin‑dependent chromatin remodeling.

Rationale

AKG is an obligate substrate for the Ten‑Eleven Translocation (TET) family of dioxygenases that drive DNA demethylation [3]. TET activity is modulated by the cellular redox state; elevated NAD+ activates sirtuins (SIRT1‑7) that deacetylate histones and transcription factors, fostering a chromatin environment conducive to TET binding and oxidation of 5‑methylcytosine [6]. Conversely, when NAD+ is low relative to AKG, excess AKG can inhibit NAD+-dependent enzymes through product competition or alter the α‑KG/NAD+‑sensitive prollyl hydroxylase domain (PHD) enzymes, leading to HIF stabilization and a pro‑inflammatory milieu that counteracts epigenetic remodeling [2]. Preliminary data show that participants with higher baseline biological age benefit more from Ca‑AKG [1], suggesting that those with a favorable NAD+/AKG milieu may already possess a senescent‑cell burden that is receptive to metabolic‑epigenetic reset.

Predictions

1. Baseline plasma NAD+/AKG ratio will positively correlate with the magnitude of epigenetic age change (ΔDNAmAge) following 6 months of Ca‑AKG supplementation.
2. Participants in the top quartile of the NAD+/AKG ratio will show at least a 5‑year greater reduction in GrimAge compared with the bottom quartile.
3. The ratio will predict changes in expression of nuclear‑encoded mitochondrial genes (NEMGs) such as TFAM, NDUFS1, and COX4I1, measured in peripheral blood mononuclear cells, via increased promoter demethylation detected by oxidative bisulfite sequencing.
4. In vitro, adding NAD+ to cultured fibroblasts will amplify TET‑mediated demethylation of the BMAL1 promoter in the presence of physiological AKG concentrations, whereas excess AKG without NAD+ will blunt this effect.

Experimental Design

• Recruit 120 middle‑aged adults (45‑65 y), stratify by baseline NAD+/AKG ratio (measured by LC‑MS).
• Randomize within each stratum to receive Ca‑AKG (1000 mg day⁻¹) or placebo for 24 weeks.
• Primary outcome: ΔDNAmAge (GrimAge) from baseline to week 24.
• Secondary outcomes: NAD+, AKG levels; global 5‑hmC; NEMG promoter methylation; mitochondrial respiration (Seahorse).
• Statistical plan: test interaction between treatment and baseline ratio using linear mixed models; pre‑specify a ratio cut‑off derived from ROC analysis.

Potential Outcomes

If the hypothesis holds, a high NAD+/AKG ratio will identify a responsive subgroup, explaining variability in prior trials and guiding precision dosing. Failure to observe a ratio‑dependent effect would refute the notion that NAD+ status gates TET‑driven demethylation in this context, prompting investigation of alternative mediators such as intracellular α‑KG compartmentalization or ketone body signaling.